Benjamin Halladay is Chief Financial Officer of Esperion Therapeutics, Inc.. Currently has a direct ownership of 240,682 shares of ESPR, which is worth approximately $454,888. The most recent transaction as insider was on Jan 17, 2025, when has been sold 9 shares (Common Stock) at a price of $2.27 per share, resulting in proceeds of $20. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 241K
1.33% 3M change
225.53% 12M change
Total Value Held $454,888

Benjamin Halladay Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jan 17 2025
SELL
Open market or private sale
$20 $2.27 p/Share
9 Reduced 0.0%
240,682 Common Stock
Dec 17 2024
SELL
Open market or private sale
$7,852 $2.42 p/Share
3,245 Reduced 1.33%
240,691 Common Stock
Mar 14 2024
BUY
Grant, award, or other acquisition
-
170,000 Added 41.07%
243,936 Common Stock
Mar 14 2023
BUY
Grant, award, or other acquisition
-
9,200 Added 11.07%
73,936 Common Stock
Dec 09 2022
BUY
Grant, award, or other acquisition
-
44,000 Added 40.83%
63,771 Common Stock
BH

Benjamin Halladay

Chief Financial Officer
Ann Arbor, MI

Track Institutional and Insider Activities on ESPR

Follow Esperion Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ESPR shares.

Notify only if

Insider Trading

Get notified when an Esperion Therapeutics, Inc. insider buys or sells ESPR shares.

Notify only if

News

Receive news related to Esperion Therapeutics, Inc.

Track Activities on ESPR